BUSINESSAug 5 · 11:17 UTCMARKETWATCHJaimy Lee

Lilly’s revenue soars 48%, driven by demand for its GLP-1s

Lilly's revenue increased by 48% due to strong demand for its GLP-1 drugs Mounjaro and Zepbound, which are used for treating Type 2 diabetes and weight loss.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

LillyorganizationMounjarotopicZepboundtopicGLP-1stopictype 2 diabetestopicweight losstopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSAug 5 · 10:57 UTC
Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
HEALTHJun 18 · 08:30 UTC
What’s next for GLP-1 weight loss drugs?
BUSINESSJun 8 · 12:00 UTC
Eli Lilly stock surged after its next-generation weight loss drug posted record results
BUSINESSJun 23 · 04:00 UTC
Eli Lilly deploys weight-loss cash on ‘App Store’ for scientists
HEALTHMay 28 · 19:08 UTC
Lilly’s GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans